Reference : In vivo quantification of dopaminergic terminals loss in Parkinson’s Disease rat mode...
Scientific congresses and symposiums : Paper published in a journal
Human health sciences : Radiology, nuclear medicine & imaging
http://hdl.handle.net/2268/188164
In vivo quantification of dopaminergic terminals loss in Parkinson’s Disease rat model: comparison between [18F]FMT and [18F]FDOPA.
English
Becker, Guillaume mailto [Université de Liège > > Centre de recherches du cyclotron >]
Bahri, Mohamed Ali mailto [Université de Liège > > Centre de recherches du cyclotron >]
Michel, Anne []
Hustadt, F []
Luxen, André mailto [Université de Liège > Département de chimie (sciences) > Laboratoire de chimie organique de synthèse >]
Garraux, Gaëtan mailto [Université de Liège > Département des sciences biomédicales et précliniques > Biochimie et physiologie du système nerveux >]
Lemaire, Christian mailto [Université de Liège > > Centre de recherches du cyclotron >]
Plenevaux, Alain mailto [Université de Liège > > Centre de recherches du cyclotron >]
Jul-2016
Molecular Imaging and Biology
Springer
18
S1
Proceedings of the World Molecular Imaging Congress 2015, Honolulu, Hawaii : Late-Breaking Abstracts
S1744
Yes (verified by ORBi)
No
International
1536-1632
1860-2002
New York
NY
World Molecular Imaging Congress 2015
02-05 September 2015
World Molecular Imaging Society
Honolulu
USA
[en] [18F]FMT ; Parkinson's disease ; [18F]DOPA ; preclinical imaging ; microPET ; 6-OHDA
[en] Objectives: Rat models of Parkinson’s disease (PD), such as unilaterally lesioned rats with 6-hydroxydopamine (6-OHDA), are useful to evaluate novel antiparkinsonian therapies. MicroPET imaging, using L-3,4-dihydroxy-6-[18F]-fluoro-phenylalanine ([18F]FDOPA) allows longitudinal evaluations of DA terminals loss. However, chemical structure of [18F]FDOPA leads to suboptimal PET imaging. 18F-fluoro-m-tyrosine ([18F]FMT) is an effective PET tracer to evaluate DA terminals integrity and L-aromatic amino acid decarboxylase (AAAD) metabolic pathway. So far, there are no available quantitative PET studies comparing the two methods in hemiparkinsonian rats. In this study, we compare imaging data provided by [18F]FMT PET and [18F]FDOPA PET in 6-OHDA-lesioned rats.

Methods: 10 µg of 6-OHDA were injected into the right medial forebrain bundle (MFB) of male Sprague-Dawley rats (n=8). As control, sham-treated rats (n=8) were injected with vehicle only but otherwise treated identically. Striatal DA presynaptic activity was assessed by dynamic PET with both [18F]FMT and [18F]FDOPA. Structural T2-weighted brain images were acquired on a 9.4T MRI and were used for co-registration. After normalization on a MRI template, kinetic analysis was performed by “Patlak Reference” model, using PMOD software. Six days after the last PET scan, rats were sacrificed, and striatum were rapidly removed for striatal DA and metabolites quantification.

Results: Striatal accumulation was observed for both tracers. However, while the administration of [18F]FDOPA required two peripheral inhibitors (benserazide and entacapone), only benserazide is needed with [18F]FMT. As consequence of the 6-OHDA-lesion, significant decrease of both [18F]FMT and [18F]DOPA accumulation was recorded in the striatum ipsilateral to the lesion. Lesioned rats had dramatically reduced uptake constant Ki in the ipsilateral striatum compared to the contralateral striatum (p<0.001 for [18F]FMT and p<0.05 for [18F]DOPA) and to the ipsilateral striatum of sham-treated rats (p<0.001 for both tracers). The DA content in the ipsilateral striatum was significantly lower (p<0.001) than in the contralateral striatum in the 6-OHDA-injected group, whereas such difference was not measured with the sham group. This indicate that [18F]FMT PET is as effective as [18F]DOPA PET to quantify loss of DA presynaptic function in unilaterally 6-OHDA lesioned rats.

Conclusions: Our results are in agreement with data reporting correlation between these two tracers in a Non-human primate model of PD. The sensitivity of the data quantification obtained in this study, confirms the interest to pursue longitudinal investigations with [18F]FMT to monitor dopaminergic dysfunction in a more progressive preclinical model of PD.
Centre de Recherches du Cyclotron - CRC
Fonds de la Recherche Scientifique (Communauté française de Belgique) - F.R.S.-FNRS
Researchers ; Professionals ; Students
http://hdl.handle.net/2268/188164

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Abstract WMIC 2015_GBECKER-1.pdfAbstractAuthor postprint181.44 kBRequest copy
Restricted access
Poster_WMIC_2015_GB.pdfPosterAuthor postprint755.75 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.